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Introduction:
SOX4 is a critical and required regulator of development and recent evidence implicates a role for SOX4 in carcinogenesis. The goal of this research is to evaluate the transcriptional and oncogenic properties of the transcription factor SOX4 and to determine its role in murine prostate development. Our lab has previously shown SOX4 mRNA and protein to be overexpressed in prostate cancer, and this expression is correlated with increasing Gleason score. Other labs have shown SOX4 to be overexpressed in other tumors such as leukemia, melanoma, glioblastoma and bladder carcinomas. Despite this knowledge little is known of the direct transcriptional targets of SOX4, and how misregulation of these networks affects human cancers and development. To determine the direct transcriptional targets on a global scale we performed chromatin immunoprecipitation coupled to DNA microarrays. We used human promoter arrays from Nimblegen, Inc. that tiled roughly 5 kb of promoter and intronic sequence for 25,000 known genes. Total coverage for the array was roughly 110 Mb of DNA. Using this technique we were able to determine the direct SOX4 targets in living prostate cancer cells. We have also obtained a SOX4 floxed mouse that will enable the prostate specific deletion of SOX4 in mice. This information will determine if SOX4 is required for the development of a functional prostate. Determining the transcriptional targets and in vivo functions of SOX4 will contribute critical knowledge to the SOX4 field.
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Body:
AIM 1: Determine the Direct Transcriptional Targets of SOX4 on a Global Scale using a ChIP-chip approach.
In order to facilitate chromatin immunoprecipitation (ChIP) of SOX4, an HA epitope tag was inserted onto the N-terminus and the HA-SOX4 construct was cloned into an eYFP expressing lentiviral vector ( Figure  1A ). RWPE-1 and LNCaP prostate cancer cell lines were stably infected with the lentivirus and fluorescenceactivated cell sorting (FACS) analysis was used to purify and pure population of eYFP expressing cells ( Figure  1B ). Two cell lines were created expressing either an eYFP only control construct or the HA-SOX4 and eYFP genes. Immunoprecipitation (IP) was performed to ensure HA-SOX4 was expressed and could be IPed using our 12CA5, anti-HA monoclonal antibody ( Figure 1C ). Both RWPE-1 and LNCaP cell lines were created but only the LNCaP-HA-SOX4 and control cells were used for the ChIP-chip experiment. ChIP assays were performed in triplicate for the LNCaP-HA-SOX4 cell lines and in duplicate using the control cell lines. DNA was extracted and purified using standard ChIP protocols from Nimblegen, Inc. IPed and total Input DNA was amplified using the ligation-mediated PCR approach and 4 ug of total DNA was sent to Nimblegen, Inc for the labeling and hybridization reactions.
Signal intensities were z-score normalized, log2 transformed and ratios of IPed to total Input signal calculated for each probe set. To identify enriched peaks ChIPoTle analysis (1) was carried out using a window of 500 bp and a step size of 50 bp. ChIPoTle software uses a sliding window approach to look for peaks that are enriched across multiple neighboring probes and assigns a p-value for a genomic region based on a Gaussian error function. Peaks that overlapped in two of the three data sets, were not present in the LNCaP-YFP cell line and scored a p-value less than 1x10 -5 were called significant ( Figure 2A ). Using this approach 139 genes contained significant overlapping peaks and were labeled direct SOX4 targets (Table 1) . To verify the set of 139 direct SOX4 target genes, 10 candidate SOX4 target genes were chosen at random, QRT-PCR primers were designed around the peaks and enrichment was verified by conventional ChIP ( Figure 2B ). All 10 of the genes were reproducibly enriched in the LNCaP-HA-SOX4 cell line as well as the RWPE-1 cell line over the YFP control ( Figure 2B ). We further validated 6 more genes that met our p-value criteria in both the LNCaP and RWPE-1cell lines by PCR ( Figure 2C and 2D). All genes tested were enriched in both cell lines except ANKRD15, which was not enriched in the RWPE-1 cell line. These results confirm the validity of our data set.
HMG domain transcription factors bind AT rich DNA in the minor groove and two previous reports identify a 7mer SOX4 binding motif (2, 3) . While this knowledge can aid in the search for putative binding sites it does not take into account the role of alternate bases at various positions. A SOX4 specific positionweight matrix is required to fully utilize the power of bioinformatic searches. Apart from the consensus core SOX family binding site WWCAAW, where W represents either A or T, little is known about what preferences SOX4 exhibits at each base position during binding (4) . In order to facilitate bioinformatic searches for SOX4 DNA binding sites we sought to determine a SOX4 specific position-weight matrix (PWM) using a unique, protein-binding, double stranded DNA microarray (5) . The array allows recombinant protein to interact with and bind every possible 10mer, thus allowing in vitro binding site specificities to be calculated. We generated an N-terminal, GST-SOX4-DBD fusion protein, and expressed and purified it from E. coli ( Figure 3B ). To ensure the purified recombinant fusion protein was functional we performed an electromobility shift assay (EMSA) using a published SOX4 binding site of AACAAAG (2) . Increasing concentrations of GST-SOX4-DBD was incubated with radiolabeled specific probe alone, with a cold specific competitor or a cold nonspecific competitor. GST-SOX4-DBD was able to bind the probe and cause a shift that was abolished when cold specific competitor probe, but not when cold non-specific probe was added ( Figure 3A) . These data show that the truncated GST-SOX4-DBD fusion protein is functionally active in vitro. The GST-SOX4-DBD was incubated with the protein binding microarray and a novel PWM (AACAA A / T G / A G /A/ C ) was calculated according to published protocols ( Figure 3C ) (5) . Two groups have previously reported similar binding site sequences for SOX4: AACAAAG (2) and AACAAT (3). Our PWM confirms both of the previous known Christopher Scharer W81XWH-07-1-0044 Annual Report 6 binding sites and adds new information on the binding preferences in the 8 th position as well as alternate bases at the 6 th and 7 th positions.
Using our newly synthesized PWM, we applied CONFAC (6) software to analyze the enriched sequences for the presence of SOX4 binding sites. We analyzed the sequences for the enriched peaks in the promoters of our 139 verified genes as well as 18 YFP enriched control sets containing peaks of equal sequence length. With stringent criteria (core similarity > 0.85, matrix similarity > 0.75) we find 83 of 139 (60%) contain at least one SOX4 binding site, and those peaks that contain SOX4 binding sites have on average 4 SOX4 sites per peak. SOX4 binding sites were significantly enriched relative to 18 sets of random, YFP enriched sequences (p < 0.0019 by Mann-Whitney U-test and Benjamini correction for multiple hypothesis testing). Previous studies have also implicated that SOX proteins mediate their transcriptional activity by interacting with other transcription factors such as the SOX2-OCT3/4 pair (4). CONFAC software was used again to search the sequences for the presence of co-occurring transcription factor binding sites. Using the same criteria as before, comparing the verified sequences to 18 random controls we determined that the E2F family was the most frequently co-occurring site with a q-value of 1.91 x 10 -8 (Table 2) . Interestingly, GO ontology analysis of the 139 SOX4 target genes revealed that 6% of them are involved in cell cycle. This finding suggests that part of SOX4's function is to control the expression of cell cycle-regulated genes ( Figure 4A ). Other co-occurring transcription factor binding sites that were overrepresented are the WHN and HEB, a forkhead and TCF transcription factor respectively. SOX4 has been previously shown to modulate WNT signaling via interaction with β-catenin and a TCF transcription factor, suggesting a possible role for SOX4 in transcriptionally modulating WNT signals (7) .
In order to determine the biological processes and functions of the SOX4 targets we performed a GO ontology analysis using GOstat software (8) . GOstat analysis annotates gene lists with GO functions and calculates an enrichment p-value with corrections for multiple hypothesis testing. GOstat analysis identified several highly enriched biological functions, including anatomical development, transcriptional regulation, protein folding, signal transduction, cell cycle regulation, angiogenesis, and cell motility. A similar gene ontology analysis using DAVID software (9) of the list of direct SOX4 targets found that the top annotated biological process was transcription (p = .024) and the top annotated molecular functions were nucleic acid (p = 6.6x ) and DNA binding (p = 2.9x ). Interestingly, the analysis identified 11 other transcription factors (Table 3) as SOX4 regulatory targets suggesting that SOX4 may regulate other transcriptional networks. Ingenuity Pathway Assist (IPA) analysis identified biological pathways and functions that are enriched in our verified gene list compared to random control lists. IPA analyses discovered key components of the EGFR, Notch, AKT-PI3K and WNT-Bcatenin pathways as SOX4 regulatory targets. Using this information we built a SOX4 regulatory network found in prostate cancer cells ( Figure 4B ). SOX4 target genes comprise key components such as ligands (DLL1 and NGR1), a regulatory kinase (PDPK1) and downstream transcription factors (FOXO3 and HES2). These data suggest that SOX4 impacts key developmental and growth factor signaling pathways in prostate cancer cells.
AIM2: Determine the effects of Loss or Overexpression in vivo
Our collaborator, Dr. Neal Copeland at the National Cancer Institute (NCI), generated a mouse containing a LOX-STOP-LOX-SOX4 allele inserted into the Rosa26 genomic locus ( Figure 5A ). This construct, when crossed to a mouse expressing Cre recombinase under the control of a prostate specific probasin promoter, causes the STOP codon to be excised allowing expression of the SOX4 transgene ( Figure  5B ). This allows the prostate specific overexpression of SOX4. Under the supervision of the Emory animal facility Rosa26-SOX4 mice were breed to Probasin-Cre mice to generate a line of Rosa26-SOX4/Probasin-Cre mice. The construct predicts that GFP expression should be lost and SOX4 expression gained. However, upon analysis of prostate RNA by quantitative real-time PCR (QRT-PCR) we detected a decrease in GFP mRNA but surprisingly no significant increase in SOX4 mRNA levels ( Figure 5C and 5D ). Pathological evaluation of prostate sections revealed no structural abnormalities and immunohistochemical staining for the presence of Christopher Scharer W81XWH-07-1-0044 Annual Report 7 SOX4 protein did not show a difference between controls and Rosa26-SOX4/Probasin-Cre mice ( Figure 6 ). Either through biological selection for lower SOX4 levels or a technical problem with expression from the Rosa26 locus, SOX4 overexpression was not detected in these mice. Unfortunately this project was discontinued and will not be studied further. Future directions include using a Tet-inducible SOX4 that does not require genomic rearrangements may provide further insights into the effects of SOX4 overexpression.
The other side to this study is to specifically knockout SOX4 in the prostate to determine the developmental requirement for SOX4. We recently received these mice from Dr. Neal Copeland. The endogenous SOX4 allele is flanked by LOXP sites. When crossed to the Probasin-Cre mice, endogenous SOX4 will be excised allowing us to study the effects of loss of SOX4 on the prostate. The Probasin promoter becomes active around birth, continues into adulthood and spans the majority of prostate development (10) .
Christopher Scharer
W81XWH-07-1-0044 Annual Report 8
Key Research Accomplishments:
• Determined 139 high confidence direct SOX4 target genes • Identified a novel PWM for SOX4 • Incorporated the PWM into bioinformatic analysis to find SOX4 binding sites • Identified the possible pathways that SOX4 influences • Evaluated the Rosa26-SOX4 mice for SOX4 overexpression and the phenotypic consequences • Established the initial breeding for the prostate specific SOX4 knockout mice Reportable Outcomes:
• Manuscripts: The research performed as described in AIM 1 is currently being prepared for submission to Genome Research and will be submitted in early 2008. • Abstracts: The research performed as described in AIM1 will be presented as a poster for the 2008 Keystone Meeting -Signaling Pathways in Cancer and Development • Presentations: All research preformed during the training grant will be presented annually at an internal department seminar as part of my graduate training program.
Conclusion:
The SOX4 field has become interesting in the last couple of years due to the recent evidence linking SOX4 to multiple developmental processes and cancers. However, despite being a transcription factor there is little knowledge about the direct SOX4 target genes and the transcriptional networks SOX4 affects. This information is critical to understanding the downstream effects of SOX4. My research has vastly expanded on previous knowledge of SOX4 transcriptional targets; identifying 139 high-confidence genes. Future work will be required to verify how SOX4 affects the predicted pathways and what the phenotypic consequences are of having too much SOX4, in the case of various cancers, or no SOX4 at all which has shown severe developmental consequences in mice.
In vivo work attempting to overexpress SOX4 alone has not shown any obvious complications to prostate development, although we were never able to show that SOX4 is in fact overexpressed in our model system. To this end a tetracycline inducible system may be developed in the future which will allow us to control SOX4 levels and will allow us to study SOX4 overexpression with a different system. The future work involving the SOX4 knockout mice will be extremely interesting given that all other tissues where SOX4 has been knocked out have shown severe consequences. 
